Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 9 months from now) | |
US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 9 months from now) | |
US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 9 months from now) | |
US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(2 years from now) |
Corlanor is owned by Amgen Inc.
Corlanor contains Ivabradine.
Corlanor has a total of 4 drug patents out of which 0 drug patents have expired.
Corlanor was authorised for market use on 22 April, 2019.
Corlanor is available in solution;oral dosage forms.
Corlanor can be used as a method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.
Drug patent challenges can be filed against Corlanor from 22 October, 2025.
The generics of Corlanor are possible to be released after 12 December, 2026.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Pediatric Exclusivity(PED) | Oct 22, 2026 |
New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
New Product(NP) | Apr 22, 2022 |
Drugs and Companies using IVABRADINE ingredient
NCE-1 date: 22 October, 2025
Market Authorisation Date: 22 April, 2019
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 9 months from now) | |
US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 9 months from now) | |
US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 9 months from now) | |
US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7361650 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(2 years from now) | |
US7879842 (Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(2 years from now) | |
US7361649 (Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(2 years from now) | |
US7867996 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(3 years from now) |
Corlanor is owned by Amgen Inc.
Corlanor contains Ivabradine Hydrochloride.
Corlanor has a total of 8 drug patents out of which 0 drug patents have expired.
Corlanor was authorised for market use on 15 April, 2015.
Corlanor is available in tablet;oral dosage forms.
Corlanor can be used as a method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.
Drug patent challenges can be filed against Corlanor from 16 October, 2019.
The generics of Corlanor are possible to be released after 12 June, 2027.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
Pediatric Exclusivity(PED) | Oct 15, 2020 |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
NCE-1 date: 16 October, 2019
Market Authorisation Date: 15 April, 2015
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: TABLET;ORAL